KYNB — KYNTRA BIO, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 921299 ·
Last close
$7.13
Market Cap
$28.86M
52W High
$7.95
52W Low
$6.32
ADV30
23,930
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,738,000 | -368,000 | -13,796,000 | -15,198,000 | 109,629,000 | 36,997,000 | 118,919,000 |
| Dec 2025 | 1,277,000 | 999,000 | -13,519,000 | -14,220,000 | 119,594,000 | 47,872,000 | 115,119,000 |
| Sep 2025 | 1,076,000 | 1,134,000 | -5,370,000 | 200,636,000 | 137,014,000 | 117,975,000 | 119,529,000 |
| Jun 2025 | 1,348,000 | 1,263,000 | -11,659,000 | -7,603,000 | 178,055,000 | 23,367,000 | 359,085,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,380,000
Investing CF
$38,453,000
Financing CF
$-85,947,000
CapEx
$-179,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$40.46
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,721,245,000
Inventory
$3,384,000
Receivables
$9,040,000
ST Investments
$50,240,000
EBIT TTM
$-47,731,000
Pretax Income TTM
$-56,663,000
Interest Exp TTM
$8,932,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,439,000
EBITDA
$-43,916,000
Free Cash Flow
$27,280,376
Enterprise Value
$-4,611,961
Total Cash
$87,237,000
Total Debt
$19,249,000
Shares Out
4,048,112
Trailing EPS
$-13.99
Book Value
$-10.82
ROE
—
ROA
-20.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,440,000 | -45,342,000 | 183,452,000 | 119,594,000 | 115,119,000 | — | -4,774,000 |
| Dec 2024 | 29,621,000 | -130,962,000 | -47,579,000 | 214,525,000 | 398,160,000 | — | -137,999,000 |
| Dec 2023 | 46,803,000 | -310,115,000 | -284,232,000 | 423,529,000 | 585,728,000 | — | -315,021,000 |
| Dec 2022 | 140,734,000 | -301,025,000 | -293,654,000 | 610,087,000 | 611,567,000 | — | -145,933,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-9.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPHI | CHINA PHARMA HOLDINGS, INC. | $28.77M | $0.71 | — |
| NNVC | NANOVIRICIDES, INC. | $28.04M | $1.22 | — |
| IGC | IGC Pharma, Inc. | $28.03M | $0.28 | — |
| SKYE | Skye Bioscience, Inc. | $27.66M | $0.79 | — |
| SER | Serina Therapeutics, Inc. | $27.60M | $1.84 | — |
News headlines (Yahoo Finance, 1h cache)
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
2026-06-11 20:05 · Yahoo
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
2026-05-12 07:07 · Yahoo
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript
2026-05-11 22:10 · Yahoo
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 22:05 · Yahoo
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-11 20:05 · Yahoo
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 12:50 · Yahoo
Kyntra Bio to Report First Quarter 2026 Financial Results
2026-05-04 20:05 · Yahoo
Replays from RedChip's Biotech Investor Conference Now Available
2026-04-20 15:00 · Yahoo
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
2026-04-14 16:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
2026-04-10 16:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.